Feb 4, 2014, 10:35 AM by Michael Croft

Bio-IT World News Brief | Thermo Fisher Scientific announced yesterday that it has finally completed its acquisition of Life Technologies, following months of preparation and negotiations with both the FTC and European Commission to approve the purchase.

Feb 4, 2014, 00:00 AM by Michael Croft

A Statement from Margaret Anderson, Executive Director, FasterCures on the NIH's New Accelerating Medicines Partnership FasterCures  applauds the  Accelerating Medicines Partnership , a new initiative launched today by the National Institutes of Health (NIH), 10 biopharmaceutical companies, and several disease-spe

Feb 4, 2014, 00:00 AM by Michael Croft

OXFORD, UK - Oxford Gene Technology (OGT), provider of innovative genetics research and biomarker solutions to advance molecular medicine, has been awarded a significant tender by the UK National Health Service for the supply of oligo-based arrays for cytogenetics.

Feb 4, 2014, 00:00 AM by Michael Croft

WESTLAKE, OH - GenomOncology today announced that the University of Pittsburgh has selected GenomOncology's GenomAnalytics™ platform and services to explore and mine the breadth of data that exists in The Cancer Genome Atlas (TCGA) . Cancer is a complex disease of the genome with each tumor h

Feb 3, 2014, 10:25 AM by Michael Croft

Boston Globe | Dicerna Pharmaceuticals, a Watertown-based company developing RNA interference therapies, showed the largest first-day gains in share price for any company since 2005 when it went public on Thursday.

Feb 3, 2014, 09:25 AM by Michael Croft

Bio-IT World | News and product releases from around the industry, including a collaboration for multiple sclerosis drug discovery, and new platforms for integrating NGS workflows and mimicking liver enzyme metabolism.

Jan 31, 2014, 14:00 PM by Michael Croft

Bio-IT World | Yesterday, Dassault Systèmes, a Paris-based company focused on Product Lifecycle Management (PLM), announced its intention to acquire Accelrys for approximately $750 million. Max Carnecchia, CEO of Accelrys, spoke with Bio-IT World this afternoon to give the announcement some context. 

Jan 31, 2014, 00:00 AM by Michael Croft

NEEDHAM, MA. - Cambridge Healthtech Institute's Insight Pharma Reports announces Ocular Disorders: Rising Therapeutics, Technologies, and Devices. The newly released Insight Pharma Report covers a handful of companies and their approach to targeting ocular diseases including wet and dry age-related macular degeneration (AMD) while also providing alternative therapeutic options for various ocular complications.

Jan 30, 2014, 12:40 PM by Michael Croft

Xconomy | Johnson & Johnson today announced that an independent group at Yale will be empowered to review and grant scientific requests to see the full results of any clinical trial in the company's records.

Jan 30, 2014, 12:20 PM by Michael Croft

Bio-IT World | GenePeeks, preparing to launch its service minimizing the risk of genetic disorders in children conceived through sperm donors, is awarded a patent for algorithms that create "digital children" from parental genotypes.

Jan 30, 2014, 08:00 AM by Michael Croft

Bio-IT World News Brief | Dassault Systèmes, a French company focused on Product Lifecycle Management (PLM), 3D design software and 3D digital Mock Up, announced its definitive agreement to acquire Accelrys last night in an all cash tender offer, representing a fully diluted equity value for Accelrys of approximately $750 million.

Jan 30, 2014, 00:00 AM by Michael Croft

NEEDHAM, MA - Cambridge Healthtech Institute (CHI) announces today the acquisition of the Knowledge Foundation, Inc.

Jan 30, 2014, 00:00 AM by Michael Croft

NEEDHAM, MA - Insight Pharma Reports announces Prenatal Diagnostics: Invasive testing, noninvasive testing, and rising maternal screening methods for preeclampsia and preterm labor report.  The newly released Insight Pharma Report discusses improvements in invasive procedures (karyotyping vs. cytogenetics), and the rise of noninvasive screening methods and their impact on prenatal healthcare.

Jan 29, 2014, 12:55 PM by Michael Croft

Bio-IT World | As a new generation of gene editing technologies like CRISPR and TALEN emerges, the founders of Editas Medicine think the time is right to forge ahead with gene therapy.

Jan 28, 2014, 07:00 AM by Michael Croft

Bio-IT World | In a paper published in Nature last week, Broad researchers identified 33 new point mutations associated with cancer and estimated that mutations associated with at least 10% of cancer cases have been IDd. The next step is to find those mutations involved in only 5% or 2% of cancers.

Jan 27, 2014, 09:10 AM by Michael Croft

Bio-IT World | It's been almost five years since the Genome Reference Consortium released a brand-new assembly of the human reference genome. The NCBI's Valerie Schneider tells Bio-IT World what "build 38" brings to the table.

Jan 24, 2014, 13:35 PM by Michael Croft

Bio-IT World | Adding to the complex picture of schizophrenia's genetics is a recent study from Iceland, looking at those individuals who carry mutations that have been linked to schizophrenia – but who have not been diagnosed with the disorder.

Jan 24, 2014, 13:00 PM by Michael Croft

Computerworld | HP is launching a suite of data center infrastructure management services based on the company's DCIM best practices that they call the Converged Management Framework.

Jan 24, 2014, 00:00 AM by Michael Croft

BERGISCH GLADBACH, GERMANY - Miltenyi Biotec announced today that the U.S. Food and Drug Administration (FDA) has approved the company’s CliniMACS CD34 Reagent System as a Humanitarian Use Device for the prevention of graft-versus-host disease (GVHD) in patients with acute myeloid leukemia (AML) in first complete remission undergoing allogeneic stem cell transplantation (SCT) from a matched related donor

Jan 22, 2014, 13:20 PM by Michael Croft

Bio-IT World | The publication of the two largest genetic studies of schizophrenia ever undertaken points to several areas of the genome as key to understanding the disease. But the research also highlights just how difficult the genetics of this complicated disorder are to untangle.